Unknown

Dataset Information

0

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.


ABSTRACT: The emergence of a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents an urgent public health crisis. Without available targeted therapies, treatment options remain limited for COVID-19 patients. Using medicinal chemistry and rational drug design strategies, we identify a 2-phenyl-1,2-benzoselenazol-3-one class of compounds targeting the SARS-CoV-2 main protease (Mpro). FRET-based screening against recombinant SARS-CoV-2 Mpro identified six compounds that inhibit proteolysis with nanomolar IC50 values. Preincubation dilution experiments and molecular docking determined that the inhibition of SARS-CoV-2 Mpro can occur by either covalent or noncovalent mechanisms, and lead E04 was determined to inhibit Mpro competitively. Lead E24 inhibited viral replication with a nanomolar EC50 value (844 nM) in SARS-CoV-2-infected Vero E6 cells and was further confirmed to impair SARS-CoV-2 replication in human lung epithelial cells and human-induced pluripotent stem cell-derived 3D lung organoids. Altogether, these studies provide a structural framework and mechanism of Mpro inhibition that should facilitate the design of future COVID-19 treatments.

SUBMITTER: Huff S 

PROVIDER: S-EPMC8491550 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8436407 | biostudies-literature
| S-EPMC7615835 | biostudies-literature
| S-EPMC9225965 | biostudies-literature
| S-EPMC10383128 | biostudies-literature
| S-EPMC7724992 | biostudies-literature
| S-EPMC9837207 | biostudies-literature
| S-EPMC9357291 | biostudies-literature
| S-EPMC8029447 | biostudies-literature
| S-EPMC8767972 | biostudies-literature
| S-EPMC10143255 | biostudies-literature